Allocation of funds procured through the exercise of stock acquisition rights has been completed. The use of proceeds comprises 1,387 million yen for research and development and 606 million yen for working capital, totaling 1,993 million yen, with allocation completed in September 2026. Future completion reports will be provided in notices regarding third-party allotments.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7776","jir_company_name":"CellSeed Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/7776-20261113-04.pdf","jir_short_summary":"Allocation of funds procured through the exercise of stock acquisition rights has been completed. The use of proceeds comprises 1,387 million yen for research and development and 606 million yen for working capital, totaling 1,993 million yen, with allocation completed in September 2026. Future completion reports will be provided in notices regarding third-party allotments.","jir_summary":"### Completion of Fund Allocation and Disclosure of Uses\nThis notice reports the completion of allocation for the 24th stock acquisition rights (with exercise price adjustment clause) issued on June 5, 2023. Specifically, of the procured amount of 1,993 million yen, allocations of 1,387 million yen to research and development and 606 million yen to working capital have been completed, and there are no remaining unallocated items. The allocation timing was September 2026. Future allocation status updates will be disclosed sequentially in notices related to the issuance and contract execution of the 25th stock acquisition rights by third-party allotment.\n\n### Future Disclosures and Impact\nEven after formal notification of allocation completion, investors should follow additional information related to third-party allotments to track the final uses and impacts of the funds. The allocation to research and development and working capital is intended to strengthen long-term growth strategy and operational stability. Investors should await the next disclosure (notice regarding issuance and contract execution of the 25th stock acquisition rights).","jir_financial_highlights":"Research and Development Funding: 1,387 million yen (Allocation Completed)\nWorking Capital: 606 million yen (Allocation Completed)\nTotal: 1,993 million yen (Allocation Completed)","jir_category":"","jir_hashtags":"#CellSeed, #CapitalPolicy, #StockAcquisitionRightsAllocationCompleted","jir_key_figures":"Total Amount Allocated: 1,993 million yen\nAmount Allocated to Research and Development: 1,387 million yen\nAmount Allocated to Working Capital: 606 million yen","jir_meta_title":"CellSeed Inc. Notice of Completion of Fund Allocation\uff5cStock Acquisition Rights Allocation Completed September 2026","jir_meta_description":"CellSeed Inc. has completed the allocation of funds procured through the 24th stock acquisition rights. Total allocation was 1,993 million yen: 1,387 million yen for R&D and 606 million yen for working capital. Information on the 25th stock acquisition rights issuance will be disclosed in due course.","jir_og_title":"CellSeed Inc. Announces Completion of Stock Acquisition Rights Allocation","jir_og_description":"Allocation of funds from the 24th stock acquisition rights has been completed and allocated to research and development and working capital. Awaiting information on the issuance of the 25th rights.","jir_og_image_url":"\/assets\/og\/company-capital_policy.jpg","jir_chart_data_collection":"[]","ir_related_company":59075,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-153372","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n